IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma

This study evaluates whether interferon-gamma (IFN-γ) expression in tumor tissue and peripheral blood can serve as a predictive biomarker of response to immune checkpoint inhibitors in the first-line treatment of metastatic melanoma. Although immune checkpoint inhibitors have substantially improved outcomes in metastatic melanoma, not all patients respond to therapy. Reliable biomarkers that could help identify patients most likely to benefit from treatment are still lacking. This study investigates the association between IFN-γ expression levels and objective treatment response. In addition, the study explores whether characteristics of the gut microbiome are associated with immunotherapy outcomes. The results may contribute to improved patient stratification and personalized treatment approaches in metastatic melanoma.

NCT Number	NCT07436390
Lead Sponsor	Institute of Oncology Ljubljana
Conditions	Metastatic Melanoma, Malignant Melanoma, Skin Cancer
Enrollment	132 participants
Start Date	2024-03-31
Primary Completion	2024-03-31 (estimated)
Study Completion	2024-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-02